|Systematic (IUPAC) name|
|ethyl 4-(methoxymethyl)-6-(phenylmethoxy) -9H-pyrido[5,4-b]indole-3-carboxylate|
|Mol. mass||390.431 g/mol|
ZK-93423 is an anxiolytic drug from the β-Carboline family, closely related to abecarnil. It is a nonbenzodiazepine GABAA agonist which is not subtype selective and stimulates α1, α2, α3, and α5-subunit containing GABAA receptors equally. It has anticonvulsant, muscle relaxant and appetite stimulating properties comparable to benzodiazepine drugs. ZK-93423 has also been used as a base to develop new and improved beta-carboline derivatives and help map the binding site of the GABAA receptor.
- Zhang H, Larock RC (December 2002). "Synthesis of beta- and gamma-carbolines by the palladium-catalyzed iminoannulation of alkynes". The Journal of Organic Chemistry 67 (26): 9318–30.
- Stephens DN, Shearman GT, Kehr W (1984). "Discriminative stimulus properties of beta-carbolines characterized as agonists and inverse agonists at central benzodiazepine receptors". Psychopharmacology 83 (3): 233–9.
- Klockgether T, Pardowitz I, Schwarz M, Sontag KH, Turski L (October 1985). "Evaluation of the muscle relaxant properties of a novel beta-carboline, ZK 93423 in rats and cats".
- Cooper SJ (January 1986). "Hyperphagic and anorectic effects of beta-carbolines in a palatable food consumption test: comparisons with triazolam and quazepam". European Journal of Pharmacology 120 (3): 257–65.
- File SE, Baldwin HA (September 1987). "Effects of beta-carbolines in animal models of anxiety". Brain Research Bulletin 19 (3): 293–9.
- Löscher W, Hönack D, Hashem A (November 1987). "Anticonvulsant efficacy of clonazepam and the beta-carboline ZK 93423 during chronic treatment in amygdala-kindled rats". European Journal of Pharmacology 143 (3): 403–14.
- Dodd RH, Ouannès C, Potier MC, Prado de Carvalho L, Rossier J, Potier P (July 1987). "Synthesis of beta-carboline-benzodiazepine hybrid molecules: use of the known structural requirements for benzodiazepine and beta-carboline binding in designing a novel, high-affinity ligand for the benzodiazepine receptor". Journal of Medicinal Chemistry 30 (7): 1248–54.
- Hollinshead SP, Trudell ML, Skolnick P, Cook JM (March 1990). "Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester". Journal of Medicinal Chemistry 33 (3): 1062–9.
- Diaz-Arauzo H, Evoniuk GE, Skolnick P, Cook JM (May 1991). "The agonist pharmacophore of the benzodiazepine receptor. Synthesis of a selective anticonvulsant/anxiolytic". Journal of Medicinal Chemistry 34 (5): 1754–6.
- Sharma RC, Ojha TN, Tiwari S, Singh P (1992). "Quantitative structure-activity relationship study of some benzodiazepine-receptor ligands having inverse agonist/antagonist and agonist actions". Drug Design and Discovery 9 (2): 135–43.
- Cox ED, Diaz-Arauzo H, Huang Q, Reddy MS, Ma C, Harris B, McKernan R, Skolnick P, Cook JM (July 1998). "Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors". Journal of Medicinal Chemistry 41 (14): 2537–52.
- Ferretti V, Gilli P, Borea PA (August 2004). "Structural features controlling the binding of beta-carbolines to the benzodiazepine receptor". Acta Crystallographica B 60 (Pt 4): 481–9.